EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is entered as of the last date set forth on the signature page below by and between LogicBio Therapeutics, Inc. (the “Company”) and [ ] (“Executive”).
CONSULTANCY AGREEMENTConsultancy Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consultancy Agreement (the “Agreement”) is entered into and effective June 1st 2021(the “Effective Date”) by and between Kyle Chiang (“Consultant”), an individual located at [**] and LogicBio Therapeutics, Inc. (“LogicBio”) with offices located at 65 Hayden Avenue, Floor 2, Lexington, MA 02421, USA. Consultant and LogicBio shall be referred to individually as a “Party” and together as the “Parties”.
CONSULTANCY AGREEMENTConsultancy Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consultancy Agreement (the “Agreement”) is entered into and effective November 6th, 2020 (the “Effective Date”) by and between Bryan Yoon (“Consultant”), an individual located at [**] and LogicBio Therapeutics, Inc. (“LogicBio”) with offices located at 65 Hayden Avenue, Floor 2, Lexington, MA 02421, USA. Consultant and LogicBio shall be referred to individually as a “Party” and together as the “Parties”.
Exclusive Research Collaboration, License and Option Agreement Between LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong LimitedExclusive Research Collaboration, License and Option Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive Research Collaboration, License and Option Agreement (this “Agreement”) is entered into as of April 26, 2021 (the “Effective Date”) by and between CANbridge Care Pharma Hong Kong Limited, a Hong Kong limited liability company, having its registered address at FLAT/RM A 12/F, ZJ300, 300 Lockhart Road, Wan Chai, Hong Kong (“CANbridge”) and LogicBio Therapeutics, Inc., a Delaware corporation having its principal place of business at 65 Hayden Ave., Floor 2, Lexington, MA 02421, United States (“LogicBio”). CANbridge and LogicBio are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LOGICBIO THERAPEUTICS, INC. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, RESTRICTED ACTIVITIES, AND ARBITRATION AGREEMENTConfidential Information, Invention Assignment, Restricted Activities, and Arbitration Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
As a condition of my employment with LogicBio Therapeutics, Inc. (“LogicBio”), its subsidiaries, affiliates, successors or assigns (together, the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, and in recognition of the fact that, as an employee of the Company, I will be granted access to the good will, trade secrets and other confidential information of the Company, and in exchange for other good and valuable consideration, including without limitation the stock option that will be granted to me, subject to the approval of the Company’s Board of Directors, under the Company’s 2018 Equity Incentive Plan on or after the date hereof, the sufficiency of which I hereby acknowledge, I agree to the following provisions of this LogicBio Therapeutics, Inc. Confidential Information, Invention Assignment, Restricted Activities, and Arbitration Agreement (this “Agreement”):
AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENTAt-Will Employment Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
As a condition of my employment with LogicBio Therapeutics, Inc., its subsidiaries, affiliates, successors or assigns (together, the "Company"), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, I agree to the following provisions of this LogicBio Therapeutics, Inc. At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (this “Agreement”):
Restricted Stock Unit AgreementRestricted Stock Unit Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a grant of Restricted Stock Units (“RSUs”) by LogicBio Therapeutics, Inc. (the “Company”) to the individual named above (the “Grantee”), an employee of the Company, pursuant to and subject to the terms of the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meanings as in the Plan.
